secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123355
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366
------------------------------------------------------------------------------

- Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.
- Cash $95.0M as of Sept 30, 2024, projected to fund operations into Q1 2026.
- Positive Phase 1a interim data for ABI-5366 (HSV) supports once-weekly and once-monthly oral dosing; Phase 1b initiated.
- Phase 1b trial for ABI-4334 (HBV) ongoing, interim data expected by end of 2024.
- ABI-1179 and ABI-6250 on track to enter clinic by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/0000950170-24-123355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/asmb-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer